Navigation Links
Peregrine Pharmaceuticals Forms Anti-Viral Research Group to Oversee Its Anti-PS Infectious Disease Collaborations
Date:10/7/2009

ists have also found that PS is exposed in certain infections caused by protozoan organisms, such as malaria and leishmaniasis.

Bavituximab, which is Peregrine's most advanced PS-targeting antibody, is currently being studied in a clinical trial for the treatment of patients co-infected with HCV and HIV. Phase I studies in HCV patients showed that bavituximab was well tolerated and it exhibited encouraging signs of anti-viral activity.

Peregrine's anti-PS antibodies are also generating positive data in preclinical HIV studies conducted by researchers from leading universities and medical research institutions in the U.S. and U.K. with funding from the Bill and Melinda Gates Foundation and the National Institutes of Allergy and Infectious Diseases (NIAID). These studies have yielded promising results that support the potential of PS-targeting agents for use as therapeutics, in vaccines and as topical microbicides, an especially promising application urgently needed in the effort to help women avoid infection with HIV and other sexually transmitted diseases such as herpes viruses and chlamydia. In addition, collaborators are also investigating the utility of PS-targeting antibodies against CMV infections and leishmaniasis, a protozoan disease that attacks people and cattle in tropical regions, with devastating effects on both health and economic well-being.

Under a major biodefense initiative funded by the Defense Threat Reduction Agency for the Transformational Medical Technologies Initiative (TMTI), bavituximab and a fully human equivalent antibody are in preclinical development for the treatment of viral hemorrhagic fevers under a contract worth up to $44.4 million. This contract, which is funding work at Peregrine and at several collaborating institutions, was awarded based on positive data from earlier studies in animals infected with VHF that was funded by a previous grant from NIAID. This work is going well, and Peregrine
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara(R) for Treatment of Brain Cancer
2. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
3. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
4. Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
5. Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrines Fully Human Anti-PS Antibody in Prostate Cancer Model
6. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
7. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
8. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
9. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
10. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... 2013  PTC Therapeutics, Inc., today announced that it ... the U.S. Securities and Exchange Commission ("SEC") relating to ... The number of shares to be offered and the ... (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) ... book-running managers for the offering. Cowen and Company is ...
(Date:5/16/2013)... and SYDNEY , May 16, ... - ASX: HIN), a leading innovator of less invasive, miniaturized ... heart failure, today announced that CEO Doug Godshall ... Global Healthcare Conference at 11:00 a.m. EDT on Monday, May ... at the Sheraton New York Hotel. A live ...
(Date:5/16/2013)... , May 16, 2013 AcelRx Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of innovative therapies for the treatment ... Richard King , President and CEO, will present a ... Sheraton New York Hotel in New York ... 2013 at 9:30 a.m. ET/6:30 a.m. PT. The ...
Breaking Medicine Technology:PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast 2AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference 2AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference 3
(Date:5/18/2013)... Children who swallow high-powered magnets often need surgery and ... a new study. The researchers, from the Louisiana ... more than 79 percent of children who swallowed very ... procedure, in which a tube containing a camera is ... these cases can be treated through observation or by ...
(Date:5/18/2013)... 18, 2013) The use of a smartphone ... according to new research presented today at Digestive ... days in advance of the procedure, includes dietary ... be taken at strict intervals. The better the ... see cancer and precancerous polyps in the colon. ...
(Date:5/18/2013)... In a May 14, 2013 article entitled ... Discovering Cancer Gene,” Fox News reported the movie star ... she carried a gene that doctors estimated gave her ... 50 percent risk of ovarian cancer (go to: goo.gl/5JHBP). ... 2013 with a blog post entitled “A Patient’s Journey: ...
(Date:5/18/2013)... 18, 2013 Today, Zane Benefits, ... agents’ role in Marketplaces . Zane Benefits, which ... sponsored health benefits, is the leader in health ... health reimbursement arrangements . , According to Zane ... Services (HHS) recently released a much-anticipated statement and ...
(Date:5/18/2013)... Serena Gordon HealthDay Reporter , , FRIDAY, May 17 ... students sometimes binge drink, but new research shows that college ... on a weekly basis than are college men. ... alcohol that,s considered safe on a weekly basis is much ... for women versus 14 for men. But, there,s good reason ...
Breaking Medicine News(10 mins):Health News:Swallowing Magnets Can Be Fatal for Children 2Health News:New smartphone application improves colonoscopy preparation 2Health News:Angelina Jolie – Scarless Breast Augmentation Surgery 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:College Women More Prone to Problem Drinking Than Men: Study 2Health News:College Women More Prone to Problem Drinking Than Men: Study 3
... ten years since dolly’s birth and scientist are still doing ... ,Dolly offered hope to millions of sick and disabled people ... the world's first clone of an adult mammal. From then ... advanced and the cloning technique has been refined. Cloning is ...
... protein named menin – involved in tumor-suppression or cell-proliferation-suppressing ... which again affected blood sugar// regulation - researchers at ... ,In humans menin gene (Men1) mutation can lead ... 1 (MEN1) and this discovery also has implications for ...
... of oral clefting leaves some with psychological problems into adulthood. ... quality of life can be used to learn about the ... ,Oral clefting is one of the most common ... and can vary by age and type of clefting. Children ...
... Antibiotics - decreased cell death and heart attack injury ... cells//. ,A study with rapamycin - an ... by Virginia Commonwealth University researchers have revealed that heart ... protected by rapamycin. ,In the July issue ...
... botox – an anti-wrinkle treatment, Dr Frederic Meunier, ... a cure for motoneuronal diseases//. ,Researcher ... system in the body, which blocked the unnecessary ... motorneuron diseases. ,Motoneuronal diseases cause a ...
... stomach cancer who receive chemotherapy before and after surgery have ... published in Thursday‘s the 5th of July, New England Journal ... of death by at least a quarter, when compared to ... shrinking the tumors and thereby improved the survival without a ...
Cached Medicine News:Health News:Dolly Paves the Way for Exhaustive Stem Cell Research 2Health News:Menin Gene Mutation made Insulin Secreting Cells to Proliferate 2Health News:Learning the Value of Prevention and Treatment in Oral Clefting 2Health News:Antibiotic Proved Protective against Heart Tissue Damage and Cell Death – Research Find 2
... well as humidification, try Flo-Mist™., ,Flo-Mist™, ... continuous medication nebulizer (CMN), engineered to deliver ... ml reservoir and jet flow design allow ... medication delivery at 25 ml/hr. Particles are ...
Nebulizer Custom Kit...
... Innovators in Anesthesia and Respiratory Products, ... quality medical devices for Anesthesia and Respiratory ... manufacture products that enhance the clinician's ability ... close attention to the bottom line. , ...
... nebulizer achieves optimum lung penetration for maximum ... is 1.04-1.10 µ at 6-8 LPM. Latex-free ... ,As the world leader in airway ... assurance of proven technology by offering top ...
Medicine Products: